Search

Your search keyword '"Inoue, Masaaki"' showing total 294 results
Start Over Author "Inoue, Masaaki"
294 results on '"Inoue, Masaaki"'

1. Efficacy and Safety of Re-administration of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) After EGFR-TKI-Induced Interstitial Lung Disease (CS-Lung-005)

Author

Kanaji, Nobuhiro, Ichihara, Eiki, Tanaka, Takaaki, Ninomiya, Takashi, Kozuki, Toshiyuki, Ishikawa, Nobuhisa, Nishii, Kazuya, Shoda, Hiroyasu, Yamaguchi, Kakuhiro, Kawakado, Keita, Toyoda, Yuko, Inoue, Masaaki, Miyatake, Nobuyuki, Watanabe, Naoki, Inoue, Takuya, Mizoguchi, Hitoshi, Komori, Yuta, Kojima, Kazuki, and Kadowaki, Norimitsu

Published
2024
Full Text
View/download PDF

2. Clinical characteristics of patients treated with immune checkpoint inhibitors in EGFR-mutant non-small cell lung cancer: CS-Lung-003 prospective observational registry study

Author

Kuribayashi, Tadahiro, Ohashi, Kadoaki, Nishii, Kazuya, Ninomiya, Kiichiro, Tsubata, Yukari, Ishikawa, Nobuhisa, Kodani, Masahiro, Kanaji, Nobuhiro, Yamasaki, Masahiro, Fujitaka, Kazunori, Kuyama, Shoichi, Takigawa, Nagio, Fujimoto, Nobukazu, Kubota, Tetsuya, Inoue, Masaaki, Fujiwara, Keiichi, Harita, Shingo, Takata, Ichiro, Takada, Kenji, Okawa, Sachi, Kiura, Katsuyuki, and Hotta, Katsuyuki

Published
2024
Full Text
View/download PDF

5. Joint Estimation of the Non-parametric Transitivity and Preferential Attachment Functions in Scientific Co-authorship Networks

Author

Inoue, Masaaki, Pham, Thong, and Shimodaira, Hidetoshi

Subjects
Physics - Physics and Society, Computer Science - Social and Information Networks, Physics - Data Analysis, Statistics and Probability, Statistics - Applications, Statistics - Computation
Abstract

We propose a statistical method to estimate simultaneously the non-parametric transitivity and preferential attachment functions in a growing network, in contrast to conventional methods that either estimate each function in isolation or assume some functional form for them. Our model is shown to be a good fit to two real-world co-authorship networks and be able to bring to light intriguing details of the preferential attachment and transitivity phenomena that would be unavailable under traditional methods. We also introduce a method to quantify the amount of contributions of those phenomena in the growth process of a network based on the probabilistic dynamic process induced by the model formula. Applying this method, we found that transitivity dominated PA in both co-authorship networks. This suggests the importance of indirect relations in scientific creative processes. The proposed methods are implemented in the R package FoFaF., Comment: 24 pages, 10 figures

Published
2019

7. A Case of Organ Injury Scaling of the American Association for the Surgery of Trauma Grade IV Pancreatic Injury in a Patient with Pancreaticoduodenectomy after Diagnosis of Main Pancreatic Duct Injury by Endoscopic Retrograde Pancreatography

Author

Inoue, Masaaki, Asai, Koji, Shigeta, Kenta, Watanabe, Ryutaro, Moriyama, Hodaka, Hagiwara, Osahiko, Nagao, Sayaka, Enomoto, Toshiyuki, Kiribayashi, Takaharu, Futawatari, Nobue, Nagata, Takuya, Watanabe, Manabu, Oharaseki, Toshiaki, Saida, Yoshihisa, Inoue, Masaaki, Asai, Koji, Shigeta, Kenta, Watanabe, Ryutaro, Moriyama, Hodaka, Hagiwara, Osahiko, Nagao, Sayaka, Enomoto, Toshiyuki, Kiribayashi, Takaharu, Futawatari, Nobue, Nagata, Takuya, Watanabe, Manabu, Oharaseki, Toshiaki, and Saida, Yoshihisa

Abstract

Case Report

Published
2024

9. Impacts of probiotics on the efficacies of immune checkpoint inhibitors with or without chemotherapy for patients with advanced non‐small‐cell lung cancer.

Author

Morita, Ayako, Ichihara, Eiki, Inoue, Koji, Fujiwara, Keiichi, Yokoyama, Toshihide, Harada, Daijiro, Ando, Chihiro, Kano, Hirohisa, Oda, Naohiro, Tamura, Tomoki, Ochi, Nobuaki, Kawai, Haruyuki, Inoue, Masaaki, Hara, Naofumi, Fujimoto, Nobukazu, Ichikawa, Hirohisa, Oze, Isao, Hotta, Katsuyuki, Maeda, Yoshinobu, and Kiura, Katsuyuki

Subjects
NON-small-cell lung carcinoma, IMMUNE checkpoint inhibitors, EPIDERMAL growth factor receptors, PROBIOTICS, IPILIMUMAB, PEMETREXED
Abstract

The relationships between the therapeutic effects of immune checkpoint inhibitors (ICIs) and the intestinal flora have attracted increasing attention. However, the effects of oral probiotics on the efficacies of ICIs used to treat non‐small‐cell lung cancer (NSCLC) remain unclear. We investigated the effects of probiotics on the efficacies of ICIs in patients treated with and without chemotherapy. We investigated patients with advanced NSCLC on ICI monotherapy or combination ICI and chemotherapy using the Okayama Lung Cancer Study Group Immunotherapy Database (OLCSG‐ID) and the Okayama Lung Cancer Study Group Immunochemotherapy Database (OLCSG‐ICD). In total, 927 patients (482 on ICI monotherapy, 445 on an ICI + chemotherapy) were enrolled. Most were male, of good performance status, smokers, and without epidermal growth factor receptor (EGFR)/anaplastic lymphoma kinase (ALK) mutations. Probiotics were administered to 19% of patients on ICI monotherapies and 17% of those on ICIs + chemotherapy. Of the former patients, progression‐free survival (PFS) and overall survival (OS) were significantly better in the probiotics group (PFS 7.9 vs. 2.9 months, hazard ratio [HR] 0.54, p <.001; OS not attained vs. 13.1 months, HR 0.45, p <.001). Among patients receiving ICI and chemotherapy, there were no significant differences in PFS between those on probiotics and not but OS was significantly better in the probiotics group (PFS 8.8 vs. 8.6 months, HR 0.89, p =.43; OS not attained vs. 22.6 months, HR 0.61, p =.03). Patients on probiotics experienced better outcomes following ICI treatment. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. Efficacy and safety of re-administration of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) after EGFR-TKI-induced interstitial lung disease (CS-Lung-005)

Author

Kanaji, Nobuhiro, primary, Ichihara, Eiki, additional, Tanaka, Takaaki, additional, Ninomiya, Takashi, additional, Kozuki, Toshiyuki, additional, Ishikawa, Nobuhisa, additional, Nishii, Kazuya, additional, Shoda, Hiroyasu, additional, Yamaguchi, Kakuhiro, additional, Kawakado, Keita, additional, Toyoda, Yuko, additional, Inoue, Masaaki, additional, Miyatake, Nobuyuki, additional, Watanabe, Naoki, additional, Inoue, Takuya, additional, Mizoguchi, Hitoshi, additional, Komori, Yuta, additional, Kojima, Kazuki, additional, and Kadowaki, Norimitsu, additional

Published
2023
Full Text
View/download PDF

15. Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)—IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201

Author

Yamamoto, Hiromasa, primary, Soh, Junichi, additional, Okumura, Norihito, additional, Suzuki, Hiroyuki, additional, Nakata, Masao, additional, Fujiwara, Toshiya, additional, Gemba, Kenichi, additional, Sano, Isao, additional, Fujinaga, Takuji, additional, Kataoka, Masafumi, additional, Terazaki, Yasuhiro, additional, Fujimoto, Nobukazu, additional, Kataoka, Kazuhiko, additional, Kosaka, Shinji, additional, Yamashita, Motohiro, additional, Inokawa, Hidetoshi, additional, Inoue, Masaaki, additional, Nakamura, Hiroshige, additional, Yamashita, Yoshinori, additional, Hotta, Katsuyuki, additional, Yoshioka, Hiroshige, additional, Morita, Satoshi, additional, Matsuo, Keitaro, additional, Sakamoto, Junichi, additional, Date, Hiroshi, additional, and Toyooka, Shinichi, additional

Published
2023
Full Text
View/download PDF

17. Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201

Author

Yamamoto, Hiromasa, Soh, Junichi, Okumura, Norihito, Suzuki, Hiroyuki, Nakata, Masao, Fujiwara, Toshiya, Gemba, Kenichi, Sano, Isao, Fujinaga, Takuji, Kataoka, Masafumi, Terazaki, Yasuhiro, Fujimoto, Nobukazu, Kataoka, Kazuhiko, Kosaka, Shinji, Yamashita, Motohiro, Inokawa, Hidetoshi, Inoue, Masaaki, Nakamura, Hiroshige, Yamashita, Yoshinori, Hotta, Katsuyuki, Yoshioka, Hiroshige, Morita, Satoshi, Matsuo, Keitaro, Sakamoto, Junichi, Date, Hiroshi, Toyooka, Shinichi, Yamamoto, Hiromasa, Soh, Junichi, Okumura, Norihito, Suzuki, Hiroyuki, Nakata, Masao, Fujiwara, Toshiya, Gemba, Kenichi, Sano, Isao, Fujinaga, Takuji, Kataoka, Masafumi, Terazaki, Yasuhiro, Fujimoto, Nobukazu, Kataoka, Kazuhiko, Kosaka, Shinji, Yamashita, Motohiro, Inokawa, Hidetoshi, Inoue, Masaaki, Nakamura, Hiroshige, Yamashita, Yoshinori, Hotta, Katsuyuki, Yoshioka, Hiroshige, Morita, Satoshi, Matsuo, Keitaro, Sakamoto, Junichi, Date, Hiroshi, and Toyooka, Shinichi

Abstract

Background It is shown that the postoperative adjuvant chemotherapy for non-small cell lung cancer (NSCLC) was associated with survival benefit in an elderly population. We aimed to analyze the feasibility and efficacy of alternate-day S-1, an oral fluoropyrimidine, for adjuvant chemotherapy in elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm) to IIIA (UICC TNM Classification of Malignant Tumours, 7th edition) NSCLC. Methods Elderly patients were randomly assigned to receive adjuvant chemotherapy for one year consisting of either alternate-day oral administration of S-1 (80 mg/m2/day) for 4 days a week (Arm A) or a daily oral administration of S-1 (80 mg/m2/day) for 14 consecutive days followed by 7-day rest (Arm B). The primary endpoint was feasibility (treatment completion rate), which was defined as the proportion of patients who completed the allocated intervention for 6 months with a relative dose intensity (RDI) of 70% or more. Results We enrolled 101 patients in which 97 patients received S-1 treatment. The treatment completion rate at 6 months was 69.4% in Arm A and 64.6% in Arm B (p = 0.67). Treatment completion rate in Arm B tended to be lower compared to Arm A, as the treatment period becomes longer (at 9 and 12 months). RDI of S-1 at 12 months and completion of S-1 administration without dose reduction or postponement at 12 months was significantly better in Arm A than in Arm B (p = 0.026 and p < 0.001, respectively). Among adverse events, anorexia, skin symptoms and lacrimation of any grade were significantly more frequent in Arm B compared with Arm A (p = 0.0036, 0.023 and 0.031, respectively). The 5-year recurrence-free survival rates were 56.9% and 65.7% for Arm A and B, respectively (p = 0.22). The 5-year overall survival rates were 68.6% and 82.0% for Arm A and B, respectively (p = 0.11). Conclusion Although several adverse effects were less frequent in Arm A, both alt

Published
2023

19. The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study

Author

Nishimura, Tomoka, primary, Ichihara, Eiki, additional, Yokoyama, Toshihide, additional, Inoue, Koji, additional, Tamura, Tomoki, additional, Sato, Ken, additional, Oda, Naohiro, additional, Kano, Hirohisa, additional, Kishino, Daizo, additional, Kawai, Haruyuki, additional, Inoue, Masaaki, additional, Ochi, Nobuaki, additional, Fujimoto, Nobukazu, additional, Ichikawa, Hirohisa, additional, Ando, Chihiro, additional, Hotta, Katsuyuki, additional, Maeda, Yoshinobu, additional, and Kiura, Katsuyuki, additional

Published
2022
Full Text
View/download PDF

20. More than one-third of advanced non-small-cell lung cancer patients do not receive immunochemotherapy due to intolerance

Author

Ando, Chihiro, primary, Ichihara, Eiki, additional, Yokoyama, Toshihide, additional, Inoue, Koji, additional, Tamura, Tomoki, additional, Fujiwara, Keiichi, additional, Oda, Naohiro, additional, Kano, Hirohisa, additional, Kishino, Daizo, additional, Watanabe, Kazuhiko, additional, Inoue, Masaaki, additional, Ochi, Nobuaki, additional, Onishi, Fumie, additional, Ichikawa, Hirohisa, additional, Kobe, Hiroshi, additional, Tachibana, Sayaka, additional, Hotta, Katsuyuki, additional, Maeda, Yoshinobu, additional, and Kiura, Katsuyuki, additional

Published
2022
Full Text
View/download PDF

24. The Effect of Pleural Effusion on Prognosis in Patients with Non-Small Cell Lung Cancer Undergoing Immunochemotherapy: A Retrospective Observational Study

Author

Nishimura, Tomoka, Ichihara, Eiki, Yokoyama, Toshihide, Inoue, Koji, Tamura, Tomoki, Sato, Ken, Oda, Naohiro, Kano, Hirohisa, Kishino, Daizo, Kawai, Haruyuki, Inoue, Masaaki, Ochi, Nobuaki, Fujimoto, Nobukazu, Ichikawa, Hirohisa, Ando, Chihiro, Hotta, Katsuyuki, Maeda, Yoshinobu, Kiura, Katsuyuki, Nishimura, Tomoka, Ichihara, Eiki, Yokoyama, Toshihide, Inoue, Koji, Tamura, Tomoki, Sato, Ken, Oda, Naohiro, Kano, Hirohisa, Kishino, Daizo, Kawai, Haruyuki, Inoue, Masaaki, Ochi, Nobuaki, Fujimoto, Nobukazu, Ichikawa, Hirohisa, Ando, Chihiro, Hotta, Katsuyuki, Maeda, Yoshinobu, and Kiura, Katsuyuki

Abstract

Simple Summary Minimal data exists on pleural effusion (PE) for non-small cell lung cancer (NSCLC) patients undergoing combined ICI and chemotherapy. We retrospectively investigated how PE affects survival outcomes in patients with NSCLC undergoing this combined therapy. We identified 478 patients who underwent combined ICI therapy and chemotherapy; 357 patients did not have PE, and 121 patients did have PE. Patients with PE had significantly shorter progression-free survival and overall survival than those without PE. In addition, bevacizumab-containing regimens did not improve the survival outcomes for patients with PE. In conclusion, PE was associated with poor outcomes among patients with NSCLC undergoing combined ICI therapy and chemotherapy. Objectives: Combined immune checkpoint inhibitor (ICI) therapy and chemotherapy has become the standard treatment for advanced non-small-cell lung cancer (NSCLC). Pleural effusion (PE) is associated with poor outcomes among patients with NSCLC undergoing chemotherapy. However, minimal data exists on PE for patients undergoing combined ICI and chemotherapy. Therefore, we investigated how PE affects survival outcomes in patients with NSCLC undergoing this combined therapy. Methods: We identified patients with advanced NSCLC undergoing chemotherapy and ICI therapy from the Okayama Lung Cancer Study Group-Immune Chemotherapy Database (OLCSG-ICD) between December 2018 and December 2020; the OLCSG-ICD includes the clinical data of patients with advanced NSCLC from 13 institutions. Then, we analyzed the treatment outcomes based on the presence of PE. Results: We identified 478 patients who underwent combined ICI therapy and chemotherapy; 357 patients did not have PE, and 121 patients did have PE. Patients with PE had significantly shorter progression-free survival (PFS) and overall survival (OS) than those without PE (median PFS: 6.2 months versus 9.1 months; p < 0.001; median OS: 16.4 months versus 27.7 months; p < 0.001). The n

Published
2022

25. Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403

Author

Oda, Naohiro, Ichihara, Eiki, Hotta, Katsuyuki, Ninomiya, Kiichiro, Ninomiya, Takashi, Kubo, Toshio, Minami, Daisuke, Murakami, Toshi, Yokoyama, Toshihide, Harada, Daijiro, Kuyama, Shoichi, Ichikawa, Hirohisa, Inoue, Koji, Kishino, Daizo, Inoue, Masaaki, Takigawa, Nagio, Shibayama, Takuo, Harita, Shingo, Tanimoto, Mitsune, and Kiura, Katsuyuki

Published
2017
Full Text
View/download PDF

31. Novel prospective umbrella-type lung cancer registry study for clarifying clinical practice patterns: CS-Lung-003 study protocol

Author

Nishii, Kazuya, Inoue, Masaaki, Obata, Hideto, Ueda, Yutaka, Kozuki, Toshiyuki, Yamasaki, Masahiro, Moritaka, Tomonori, Awaya, Yoshikazu, Sugimoto, Keisuke, Gemba, Kenichi, Kuyama, Shoichi, Ichikawa, Hirohisa, Shibayama, Takuo, Kubota, Tetsuya, Kodani, Masahiro, Kishino, Daizo, Fujimoto, Nobukazu, Ishikawa, Nobuhisa, Tsubata, Yukari, Ishii, Tomoya, Fujitaka, Kazunori, Hotta, Katsuyuki, Kiura, Katsuyuki, Nishii, Kazuya, Inoue, Masaaki, Obata, Hideto, Ueda, Yutaka, Kozuki, Toshiyuki, Yamasaki, Masahiro, Moritaka, Tomonori, Awaya, Yoshikazu, Sugimoto, Keisuke, Gemba, Kenichi, Kuyama, Shoichi, Ichikawa, Hirohisa, Shibayama, Takuo, Kubota, Tetsuya, Kodani, Masahiro, Kishino, Daizo, Fujimoto, Nobukazu, Ishikawa, Nobuhisa, Tsubata, Yukari, Ishii, Tomoya, Fujitaka, Kazunori, Hotta, Katsuyuki, and Kiura, Katsuyuki

Abstract

Introduction Conventional cancer registries are suitable for simple surveillance of cancer patients, including disease frequency and distribution, demographics, and prognosis; however, the collected data are inadequate to clarify comprehensively diverse clinical questions in daily practice. Methods We constructed an umbrella‐type lung cancer patient registry (CS‐Lung‐003) integrating multiple related prospective observational studies (linked studies) that reflect clinical questions about lung cancer treatment. The primary endpoint of this registry is to clarify daily clinical practice patterns in lung cancer treatment; a key inclusion criterion is pathologically diagnosed lung cancer. Under this registry, indispensable clinical items are detected in advance across all active linked studies and gathered prospectively and systematically to avoid excessive or insufficient data collection. Researchers are to input information mutually, irrespective of the relevance to each researcher's own study. Linked studies under the umbrella of the CS‐Lung‐003 registry will be updated annually with newly raised clinical questions; some linked studies will be newly created, while others will be deleted after the completion of the analysis. Enrollment began in July 2017. Discussion We successfully launched the umbrella‐type CS‐Lung‐003 registry. Under this single registry, researchers collaborate on patient registration and data provision for their own and other studies. Thus, the registry will produce results for multiple domains of study, providing answers to questions about lung cancer treatment raised by other researchers. Through such analysis of each linked study, this registry will contribute to the comprehensive elucidation of actual daily practice patterns in lung cancer treatment. Key points CS‐Lung‐003 registry directly integrates multiple linked studies created under the umbrella of this cancer registry to solve various clinical question

Published
2021

36. Novel prospective umbrella‐type lung cancer registry study for clarifying clinical practice patterns: CS‐Lung ‐003 study protocol

Author

Nishii, Kazuya, primary, Inoue, Masaaki, additional, Obata, Hideto, additional, Ueda, Yutaka, additional, Kozuki, Toshiyuki, additional, Yamasaki, Masahiro, additional, Moritaka, Tomonori, additional, Awaya, Yoshikazu, additional, Sugimoto, Keisuke, additional, Gemba, Kenichi, additional, Kuyama, Shoichi, additional, Ichikawa, Hirohisa, additional, Shibayama, Takuo, additional, Kubota, Tetsuya, additional, Kodani, Masahiro, additional, Kishino, Daizo, additional, Fujimoto, Nobukazu, additional, Ishikawa, Nobuhisa, additional, Tsubata, Yukari, additional, Ishii, Tomoya, additional, Fujitaka, Kazunori, additional, Hotta, Katsuyuki, additional, and Kiura, Katsuyuki, additional

Published
2021
Full Text
View/download PDF

38. Impact of HER2 expression on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS study subset analysis

Author

Ohashi, Kadoaki, primary, Ninomiya, Kiichiro, additional, Yoshioka, Hiroshige, additional, Bessho, Akihiro, additional, Shibayama, Takuo, additional, Aoe, Keisuke, additional, Ishikawa, Nobuhisa, additional, Kozuki, Toshiyuki, additional, Kawai, Haruyuki, additional, Kuyama, Shoichi, additional, Miyoshi, Seigo, additional, Fujitaka, Kazunori, additional, Obata, Hideto, additional, Tsubata, Yukari, additional, Awaya, Yoshikazu, additional, Inoue, Masaaki, additional, Inoue, Koji, additional, Horita, Naokatsu, additional, Yanai, Hiroyuki, additional, Hotta, Katsuyuki, additional, and Kiura, Katsuyuki, additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results